Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glioblastoma treatment patterns and outcomes over 18 years in an Irish cancer centre.

Irish journal of medical science·2026
Same author

Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.

Clinical genitourinary cancer·2026
Same author

Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group.

European urology·2026
Same author

Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.

Clinical genitourinary cancer·2026
Same author

Determinants of sensitivity to HER2-targeted antibody drug conjugates in urothelial cancer.

Nature communications·2025

Related Experiment Video

Updated: May 9, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Actionable mutations in muscle-invasive bladder cancer.

Richard M Bambury1, Jonathan E Rosenberg

  • 1Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY 10065, USA. bamburyr@mskcc.org

Current Opinion in Urology
|August 3, 2013
PubMed
Summary

Targeted therapies show promise for muscle-invasive bladder cancer, but identifying predictive biomarkers and improving genetic testing are crucial for patient benefit.

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Related Experiment Videos

Last Updated: May 9, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Muscle-invasive bladder cancer affects 35% of patients, with current treatments offering a 50% relapse rate.
  • Standard care involves neoadjuvant chemotherapy followed by radical cystoprostatectomy or chemoradiotherapy.
  • Despite aggressive treatment, many patients with muscle-invasive bladder cancer experience disease recurrence.

Purpose of the Study:

  • To review the current landscape of targeted therapies for muscle-invasive bladder cancer.
  • To explore novel treatment strategies focusing on genetic alterations.
  • To identify challenges and future directions in bladder cancer treatment.

Main Methods:

  • Review of recent clinical trials and research on targeted therapies for bladder cancer.
  • Analysis of genetic targets and biomarkers under investigation.
  • Evaluation of the efficacy of systemic platinum-based chemotherapy in specific patient subgroups.

Main Results:

  • Targeted therapies have shown success in other solid tumors but lack proven clinical benefit in bladder cancer to date.
  • Investigational targets include HER2, epidermal growth factor receptors, fibroblast growth factor receptor 3, and mTOR.
  • Research is ongoing to identify genetic profiles that predict response to platinum-based chemotherapy.

Conclusions:

  • Clinical trials are actively exploring treatments targeting actionable genetic mutations in bladder cancer.
  • Identifying predictive biomarkers is key to maximizing treatment efficacy.
  • Development of safe combination therapies and accessible genetic testing are essential for advancing bladder cancer care.